TN

Tango Therapeutics IncNASDAQ TNGX Stock Report

Last reporting period 30 Sep, 2024

Updated 20 Dec, 2024

Last price

Market cap $B

0.798

Micro

Exchange

XNAS - Nasdaq

TNGX Stock Analysis

TN

Uncovered

Tango Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-5/100

Low score

Market cap $B

0.798

Dividend yield

Shares outstanding

88.177 B

Tango Therapeutics, Inc. operates as a biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 109 full-time employees. The company went IPO on 2020-09-03. The Company’s product candidates include TNG908 and ubiquitin-specific protease 1 (USP1). TNG908, is a synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), which is designed to work selectively in cancer cells with a methylthioadenosine phosphorylase (MTAP) deletion. MTAP-deletion occurs in all human tumors, including non-small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, cholangiocarcinoma and glioblastoma. The firm is focused on initiating a Phase I/II clinical trial. USP1 is a synthetic lethal target discovery screen for BRCA1-mutant breast cancer. The Company’s lead molecules also have activity in BRCA2-mutant patient derived xenografts, including both BRCA1 and BRCA2 mutant models that are intrinsically resistant to polymerase (PARP) inhibition.

View Section: Eyestock Rating